GW 9662, PPARgamma antagonist (ab141125)
Key features and details
- Selective PPARγ antagonist
- CAS Number: 22978-25-2
- Purity: > 99%
- Soluble in ethanol to 50 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
GW 9662, PPARgamma antagonist -
製品の詳細
Selective PPARγ antagonist -
生理活性の詳細
Selective PPARγ antagonist (IC50 values are 3.3, 32, >1000 nM for PPARγ, PPARα and PPARδ respectively). Apoptotic and antimetastatic activity in vitro.
-
精製度
> 99% -
CAS 番号
22978-25-2 -
構造式
製品の特性
-
体系名
2-Chloro-5-nitro-N-phenylbenzamide -
分子量
276.68 -
分子式
C13H9ClN2O3 -
PubChem 登録番号
644213 -
保存方法
Store at +4°C. The product can be stored for up to 12 months. -
溶解性
Soluble in ethanol to 50 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
O=C(Nc1ccccc1)c2cc(ccc2Cl)[N+]([O-])=O -
由来
Synthetic
-
研究分野
- Epigenetics and Nuclear Signaling
- Transcription
- Domain Families
- HLH / Leucine Zipper
- Helix-Turn-Helix
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Retinoic & Retinoid
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
- Orphan Nuclear Receptors
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Nucleotide metabolism
- Molecular processes
- Mitochondrial transcription
画像
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (10)
ab141125 は 10 報の論文で使用されています。
- Xu L et al. PEDF inhibits LPS-induced acute lung injury in rats and promotes lung epithelial cell survival by upregulating PPAR-γ. BMC Pulm Med 23:359 (2023). PubMed: 37740176
- Huang W et al. Sildenafil protects against pulmonary hypertension induced by hypoxia in neonatal rats via activation of PPAR?-mediated downregulation of TRPC. Int J Mol Med 49:N/A (2022). PubMed: 34935055
- Qin X et al. PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model. Respir Res 23:100 (2022). PubMed: 35459189
- Shoaito H et al. The Role of Peroxisome Proliferator–Activated Receptor Gamma (PPAR?) in Mono(2-ethylhexyl) Phthalate (MEHP)-Mediated Cytotrophoblast Differentiation. Environ Health Perspect 127:27003 (2019). PubMed: 30810372
- Liu L et al. Hydroxysafflor-Yellow A Induces Human Gastric Carcinoma BGC-823 Cell Apoptosis by Activating Peroxisome Proliferator-Activated Receptor Gamma (PPAR?). Med Sci Monit 24:803-811 (2018). PubMed: 29417935
- García C et al. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR? receptor. J Neuroinflammation 15:19 (2018). PubMed: 29338785
- Degrelle SA et al. New Transcriptional Reporters to Quantify and Monitor PPAR?Activity. PPAR Res 2017:6139107 (2017). PubMed: 29225614
- Zhu HY et al. Peroxisome proliferator-activated receptor-? agonist troglitazone suppresses transforming growth factor-ß1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro. Am J Transl Res 8:3460-70 (2016). PubMed: 27648136
- Jin X et al. Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation. FEBS J 283:2295-308 (2016). PubMed: 27062545
- Zhu HY et al. Peroxisome proliferator-activated receptor-? agonist inhibits collagen synthesis in human keloid fibroblasts by suppression of early growth response-1 expression through upregulation of miR-543 expression. Am J Cancer Res 6:1358-70 (2016). PubMed: 27429849